PSMA PET/CT 前列腺内病灶 SUVmax 与根治性前列腺切除术后不良病理的相关性
本研究纳入 544 例中高危前列腺癌患者,分析 PSMA PET/CT 前列腺内病灶 SUVmax 与根治性前列腺切除术后不良病理的关系。中位病灶 SUVmax 为 9.5,中位随访 24.6 个月,SUVmax≥9.5 是术后非器官局限性疾病和不良病理的独立预测因素,且与更差的生化复发无生存相关。
要点
- PSMA PET/CT 前列腺内病灶 SUVmax≥9.5 可独立预测根治性前列腺切除术后不良病理。
- SUVmax≥9.5 患者术后 48 个月生化复发无生存率低于 SUVmax<9.5 患者(62.2% vs 72.1%,p=0.03)。
- 该指标有助于术前识别高危患者并辅助治疗决策。
核心结论
- PSMA PET/CT 前列腺内病灶 SUVmax≥9.5 是根治性前列腺切除术后不良病理的独立预测因素,并与更差的生化复发无生存相关。
研究设计与样本
- 回顾性队列研究,纳入 2016 至 2021 年间在高容量中心数据库中有术前 PSMA PET/CT 前列腺内 SUVmax 的中高危前列腺癌患者 544 例。
主要发现
- 中位病灶前列腺内 SUVmax 为 9.5,术前中位 PSA 为 8.1 ng/ml。
- D'Amico 中危和高危患者分别占 50.7% 和 49.3%,中位随访 24.6 个月。
- SUVmax<9.5 与≥9.5 患者术后 48 个月生化复发无生存率分别为 72.1% 和 62.2%(p=0.03)。
- Logistic 回归模型中,SUVmax(连续变量及以<9.5 vs ≥9.5 分层)为非器官局限性疾病和不良病理的独立预测因素。
临床怎么用
- 术前 PSMA PET/CT 测量前列腺内病灶 SUVmax 可辅助识别根治性前列腺切除术后不良病理高风险患者。
- SUVmax≥9.5 提示术后生化复发风险较高,可考虑加强术后随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a novel staging modality for prostate cancer (PCa) patients with a high positive predictive value for lesions within and outside of the prostate. To assess the ability of the maximum standardized uptake value (SUVmax) at PSMA PET/CT to predict adverse pathology at radical prostatectomy (RP). MATERIAL AND METHODS: Within a high-volume center database, we identified intermediate and high-risk PCa patients who had a PSMA PET/CT with an available intraprostatic SUVmax before RP between 2016 and 2021. Logistic regression modeling was used to test for the ability of SUVmax to predict non-organ confined disease or adverse pathology (non-organ confined and/or Gleason grade group ≥3) during RP. Kaplan-Meier analyses were used to compare biochemical recurrence (BCR)-free survival after RP stratified according to SUVmax. RESULTS: Overall, 544 patients were identified. Of those, median lesional intraprostatic SUVmax was 9.5 at PSMA PET/CT. Median PSA was 8.1 ng/ml prior to RP. 50.7% vs. 49.3% had D'Amico intermediate and high-risk characteristics. Median follow-up was 24.6 months. BCR-free survival at 48 months after RP was 72.1% vs. 62.2% (p = 0.03) for patients with SUVmax <9.5 vs. SUVmax ≥9.5 at PSMA PET. In logistic regression models, SUVmax (continuously coded and stratified in <9.5 vs. ≥9.5) represented an independent predictor for non-organ confined disease and adverse pathology. CONCLUSIONS: SUVmax ≥9.5 at PSMA PET/CT is an independent predictor of adverse pathology at RP. Moreover, it is associated with worse BCR-free survival after RP.
引用
- Preisser F, Nohe F, Herrmann K, et al. Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy. Prostate Cancer Prostatic Dis. 2026. PMID: 42637826. doi:10.1038/s41391-026-01137-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。